Research: Sanofi Pasteur, Medimrnune (AstraZeneca), Pfizer, Diassess, Novavax, Merck, GSK, Regeneron, Janssen, Novartis

Size: px
Start display at page:

Download "Research: Sanofi Pasteur, Medimrnune (AstraZeneca), Pfizer, Diassess, Novavax, Merck, GSK, Regeneron, Janssen, Novartis"

Transcription

1 Joseph Domachowske MD, FAAP Professor of Pediatrics Professor of Microbiology and Immunology SUNY Upstate Medical University Syracuse, NY Consultant: Sanofi Pasteur, Medimmune Research: Sanofi Pasteur, Medimrnune (AstraZeneca), Pfizer, Diassess, Novavax, Merck, GSK, Regeneron, Janssen, Novartis 1

2 Attendees will list the steps required and general timeline needed to move a preclinical vaccine idea to a vaccine that is available for widespread use Attendees will describe strategies for immunization and disease prevention Smallpox Diphtheria Polio Measles H. Flu b Tetanus Pertussis Pre vaccine Morbidity 29,005 21,053 16, ,217 20, ,752 Recent reported cases in US ,639 % Decrease 100% 100% >99% >99% >99% 96% 86% CDC. Impact of Vaccines in the 20 th and 21 st century. Pink Book, Appendix E

3 Vaccines licensed for use in the US Adenovirus Diphtheria, tetanus, acellular pertussis Japanese encephalitis virus Measles, mumps, rubella Rotavirus Smallpox H. influenzae type b Meningococcal Typhoid ACWY Hepatitis A Meningococcal B Varicella Hepatitis B Pneumococcal Yellow Fever Human Polio Zoster papillomavirus Influenza Rabies Cholera 3

4 Highly regulated process Can take years from concept to recommendation Most vaccines do not make it past pre clinical or early clinical trials (phase I) Vaccines Years to approval Varicella LAIV HPV* Rotavirus* Pediatric combination vaccines * Excluding early pre clinical work Douglas RG. (2008). The Vaccine Industry. In Plotkin s Vaccines. (p39). Elsevier 4

5 Demand for vaccine in market Drivers of vaccine development Technically feasible Limited use product years before marketing Uncertain demand in market Incorporation into immunization program Clinical Economic Vaccine development Clinical development Process development Assay development Vaccine effect on patients Safety, efficacy, immunogenicity Phase I, II, III clinical trials Vaccine prep by regulatory requirements Vaccine lots Consistent manufacturing methods Specific testing methods: Purity Stability Potency Assays for immunologic endpoints 5

6 Vaccine Development Pre clinical Phase I Phase II Phase III File Phase IV 1 10 years 2 3 years 2 5 years Vaccine concept Lab assays, animal models Identification of antigens 6

7 IND Application Manufacturing process Vaccine composition Pre clinical data Proposed clinical trials plan Vaccine safety Vaccine potency Vaccine efficacy Vaccine purity Small studies healthy subjects (~50) Short term Primary outcome Safety Phase I Other measures Prelim Immunogenicity Vaccine dosing Subjects at low risk for infection 7

8 RSV month old, RSV sero positive infants Safety, reactogenicity, immunogenicity Dose escalation, with safety assessments Precursor to studying vaccination in sero negative infants Longer, larger ~2 years 1,000 subjects At risk population Expanded data Safety Vaccine dosing Phase II Proof of concept Immunogenicity Double blinded, placebo controlled, randomized 8

9 RSV monoclonal antibody, extended half life Healthy pre term infants, /7 weeks Entering first RSV season Efficacy: reduction in medically attended respiratory infections due to RSV Large scale 1000s of subjects At risk for infection Several years Phase III Assess Safety Efficacy Immunogenicity Clinical endpoints Immunologic response Randomized, placebocontrolled, blinded 9

10 RSV F nanoparticle vaccine Healthy third trimester pregnant women Immunologic endpoints Pregnant women Cord blood Newborns Clinical endpoints infants for 2 years Safety data collected Biologics License Application (BLA) submission Submit safety/efficacy to FDA Vaccines and related Biologic Product Advisory Committee Review data with VRBPAC months Pre approval inspection of vaccine production 10

11 FDA Decides on licensure Restricted to study population ACIP Reviews data in context of current needs Makes vaccine recommendation FDA label indication Tdap one dose and done Tdap for people aged years Quadrivalent meningococcal one dose MenB years of age Influenza vaccine not specifically licensed for use during pregnancy ACIP recommendation Tdap every pregnancy Tdap for all 7years and older Quad mening 2 doses for all teens MenB 10 years and older for those at risk Influenza vaccine during pregnancy 11

12 Post licensure surveillance Safety surveillance VAERS, Vaccine Safety Data Link, manufacturer reports Case controlled studies when Red Flags appear Look for rare adverse events Long term efficacy evaluation During outbreaks, ongoing epidemiologic data collection Manufacturer production activities Cost of developing new vaccine $231 million in 1991 $800 million in 2010 Research and development costs of failed products Post licensure clinical studies Improvements in manufacturing processes 12

13 Private Vaccine Companies Government agencies CDC, FDA, DOD, USAID, NIH NGO Gates Foundation, PATH Contributions to Vaccine R&D Highly regulated Single set of rules applied to all vaccines Regulations of manufacturing process Regulations of clinical trials Complicated, costly, with more failures than successes 13

14 Clinicaltrials.gov Search: vaccine 6,670 registered vaccine trials 1,100 open vaccine trials 642 trials actively recruiting 14

15 clinicaltrials.gov clinicaltrials.gov 15

16 universal flu vaccine group B strep Meningococcal ABCWY RSV Ebola MERS CoV Ebola Pneumococcus Hepatitis C Malaria Meningococcal ACWY Shigella Hexavalent peds Tuberculosis RSV HIV Universal flu CMV Rabies Tdap 16

17 pneumococcus Men ACWY rotavirus VZV C. diff MMR Ebola Flu RSV 17

18 Virus attachment to host cell Virus entry into host cell cdc.gov Types A, B, C A, B: most of human disease C: uncommonly causes human disease Influenza A H1, H2, H3; N1, N2 Seasonal epidemics Vaccination is most effective method for disease prevention 18

19 IIV: intradermal, IM Trivalent, quadrivalent A (H1N1) A (H3, N2) B LAIV: intranasal Cell based Egg based Recombinant CDC and WHO provide candidate vaccine viruses Egg based: Virus injected into fertilized hen s egg Cell based: Virus inoculated into mammalian cells Recombinant: HA protein isolated from wild type virus and combined with proteins to grow in insect cells incubate for virus replication virus containing fluid harvested virus inactivated and purified FDA testing, approval, shipment 19

20 Vaccine efficacy ~30 60% Most effective when vaccine strains closely match circulating viruses Circulating strains change yearly Do not protect against pandemics Universal influenza vaccine??? Goals At least 75% effective Protects against multiple types of influenza A (pandemic strains included ) Duration over a year Suitable for all age groups conditions/universal influenza vaccine research 20

21 Current vaccines induce antibody to HA head Changes frequently Lofano, Giuseppe & Kumar, Arun & Finco, Oretta & Del Giudice, Giuseppe & Bertholet, Sylvie. (2015). B Cells and Functional Antibody Responses to Combat Influenza. Frontiers in immunology /fimmu More conserved Vaccine to induce antibody to stalk Lofano, Giuseppe & Kumar, Arun & Finco, Oretta & Del Giudice, Giuseppe & Bertholet, Sylvie. (2015). B Cells and Functional Antibody Responses to Combat Influenza. Frontiers in immunology /fimmu

22 nanoparticles 4 H subtypes into one vaccine More conserved Vaccine to induce antibody to stalk DNA based vaccine prime [phase 1, 2] M 001: antigenic peptides from many strains [phase 2] Lofano, Giuseppe & Kumar, Arun & Finco, Oretta & Del Giudice, Giuseppe & Bertholet, Sylvie. (2015). B Cells and Functional Antibody Responses to Combat Influenza. Frontiers in immunology /fimmu

23 F glycoprotein Mediates fusion reaction delivery of virus capsid core contents into cell Disrupting activity would reduce virus entry into cell protect host from infection Highly conserved among strains Infants Active immunization Passive immunization Pregnant mothers RSV Ab efficiently transferred across placenta High cord blood RSV Ab levels incidence of severe RSV LRTI Passive immunization lower 23

24 Formalin inactivated RSV vaccine Infants 2 7 months of age Enhanced disease Hospitalizations: 80% of vaccinated vs 5% placebo 2 deaths from RSV infection among vaccinated Thought to be due to Ab produced: non neutralizing and did not inhibit fusion Inflammatory CD4 T cell driven cytokine response Live Attenuated Whole Inactivated Particle based Subunit Nucleic Acid Vectors Immunoprophylaxis 24

25 ID genetic sequence of RSV F protein Clone gene into baculovirus Spodoptera frugiperda (Fall armyworm) Engineered baculovirus infects the SF9 cells Only infects insects Engineered to express genes of interest Used to infect Sf9 cells to efficiently produce desired protein RSV F proteins produced Transported to surface, extracted, purified Safe and inexpensive High capacity Infect cells Express encoded antigens Induce immune response Adenovirus type 5 Most common human Adenovirus serotype 30% + Ad Ab less immunogenic Can express multiple proteins Chimpanzee adenovirus Related to human adenovirus Low neutralizing antibodies in human population Genetically engineered recombinant CHAd155 Same vector used in ebola vaccine Non-alum composition core fibre Double stranded DNA Target RSV genes 25

26 Passive protection Palivizumab Prevention of RSV Licensed in 1998 Monthly injections during RSV season Costly YTE technology substitutes 3amino acids in the Fc region of IgG. recombinant human IgG1 kappa monoclonal antibody Targets prefusion F Derived from D25 (human mab with 100x greater potency than palivizumab in vitro YTE technology 26

27 Rigorous regulations in vaccine development Significant amount of time and money to ensure safe and effective vaccines Novel vaccine strategies are being developed to improve disease prevention New vaccines are becoming available in the US and worldwide 27

I am the principal investigator for clinical trials sponsored by Janssen and Hoffman La Roche Ltd.

I am the principal investigator for clinical trials sponsored by Janssen and Hoffman La Roche Ltd. Manika Suryadevara, MD Associate Professor of Pediatrics SUNY Upstate Medical University Syracuse, NY I am the principal investigator for clinical trials sponsored by Janssen and Hoffman La Roche Ltd.

More information

CHAPTER ONE: EXECUTIVE SUMMARY. The Global Vaccine Industry CHAPTER TWO: INTRODUCTION TO VACCINES

CHAPTER ONE: EXECUTIVE SUMMARY. The Global Vaccine Industry CHAPTER TWO: INTRODUCTION TO VACCINES CHAPTER ONE: EXECUTIVE SUMMARY The Global Vaccine Industry o Scope and Methodology o Overview o Pediatric Preventative Vaccines o The Market o Adult Preventative Vaccines o The Market o Total Market o

More information

Table Of Contents Executive Summary Introduction to Vaccines Pediatric Preventive Vaccines

Table Of Contents Executive Summary Introduction to Vaccines Pediatric Preventive Vaccines Table Of Contents Executive Summary THE GLOBAL VACCINES INDUSTRY Scope and Methodology Overview Pediatric Preventative Vaccines THE MARKET Adult Preventative Vaccines THE MARKET TOTAL MARKET ISSUES AND

More information

Preventative Vaccines. Vaccines for Special Populations. Vaccinations for Adults: An Update. Vaccines Generally Available in the U.S.

Preventative Vaccines. Vaccines for Special Populations. Vaccinations for Adults: An Update. Vaccines Generally Available in the U.S. Vaccinations for Adults: An Update Preventative Vaccines Need to be extremely safe Even greater issue as disease prevalence wanes or uncommon diseases targeted Lisa G. Winston, MD University of California,

More information

Vaccinations for Adults

Vaccinations for Adults Case: Vaccinations for Adults Lisa Winston, MD University of California, San Francisco San Francisco General Hospital A 30-year old healthy woman comes for a routine visit. She is recently married and

More information

9/10/2018. Principles of Vaccination. Immunity. Antigen. September 2018

9/10/2018. Principles of Vaccination. Immunity. Antigen. September 2018 Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Principles of Vaccination September 2018 Chapter 1 September 2018 Photographs and images included in

More information

Guidelines for Vaccinating Pregnant Women

Guidelines for Vaccinating Pregnant Women Guidelines for Vaccinating Pregnant Women March 2012 Guidelines for Vaccinating Pregnant Women Abstracted from recommendations of the Advisory Committee on Immunization Practices (ACIP) MARCH 2012 Risk

More information

Copyright regulations Warning

Copyright regulations Warning COMMONWEALTH OF AUSTRALIA Copyright regulations 1969 Warning This material has been reproduced and communicated to you by or on behalf of the University of Melbourne pursuant to part VB of the Copyright

More information

Economics of Vaccine Development A Vaccine Manufacturer s Perspective

Economics of Vaccine Development A Vaccine Manufacturer s Perspective Economics of Vaccine Development A Vaccine Manufacturer s Perspective Gerald Voss The Value of Vaccines 2 29 diseases are currently preventable by vaccination Global public health Cervical cancer 1 Diphtheria

More information

Guidelines for Vaccinating Pregnant Women

Guidelines for Vaccinating Pregnant Women Guidelines for Vaccinating Pregnant Women April 2013 Guidelines for Vaccinating Pregnant Women Abstracted from recommendations of the Advisory Committee on Immunization Practices (ACIP) April 2013 Risk

More information

APEC Guidelines Immunizations

APEC Guidelines Immunizations Pregnancy provides an excellent opportunity to enhance a woman s protection against disease and to provide protection to the neonate during the first 3 to 6 months of life. Women of childbearing age should

More information

Walter A. Orenstein, M.D. Professor of Medicine and Pediatrics Director, Emory Vaccine Policy and Development Associate Director, Emory Vaccine Center

Walter A. Orenstein, M.D. Professor of Medicine and Pediatrics Director, Emory Vaccine Policy and Development Associate Director, Emory Vaccine Center Could Vaccines be a Possible Model For Pediatric Drug Development? June 13, 2006 Walter A. Orenstein, M.D. Professor of Medicine and Pediatrics Director, Emory Vaccine Policy and Development Associate

More information

Trends in vaccinology

Trends in vaccinology Trends in vaccinology Mathieu Peeters, MD Joint Conference of European Human Pharmacological Societies and Joint Conference of European Human Pharmacological Societies and 20th Anniversary of AGAH March

More information

Principles of Vaccination

Principles of Vaccination Immunology and Vaccine-Preventable Diseases Immunology is a complicated subject, and a detailed discussion of it is beyond the scope of this text. However, an understanding of the basic function of the

More information

Stainless-steel vs Single-use: The Vaccines Perspective

Stainless-steel vs Single-use: The Vaccines Perspective Stainless-steel vs Single-use: The Vaccines Perspective CMO-Biomanufacturer Panel Tue 21 April, Noon-1:30pm, Exhibit Hall Daniel C.Vellom, PhD Sr. Director Global Technology Innovation 2015 INTERPHEX 1

More information

Vaccinology Overview. Complexity of the Vaccine Approval Process Including Lessons Learned

Vaccinology Overview. Complexity of the Vaccine Approval Process Including Lessons Learned Vaccinology Overview Complexity of the Vaccine Approval Process Including Lessons Learned Larry K. Pickering, MD, FAAP, FIDSA, FPIDS August 18, 2018 Faculty Disclosure Information In the past 12 months,

More information

These slides are the property of the presenter. Do not duplicate without express written consent.

These slides are the property of the presenter. Do not duplicate without express written consent. Cancer Survivorship Protecting Against Vaccine Preventable Diseases Heidi Loynes BSN, RN Immunization Nurse Educator Michigan Department of health and Human Services (MDHHS) loynesh@michigan.gov Are Vaccine-Preventable

More information

Sanofi Pasteur: A partner in eradicating vaccine preventable diseases and improving access to vaccines

Sanofi Pasteur: A partner in eradicating vaccine preventable diseases and improving access to vaccines Sanofi Pasteur: A partner in eradicating vaccine preventable diseases and improving access to vaccines 1 Vaccines: the single most effective medical intervention 2 Vaccines save lives Millions of cases

More information

Annex 1. WHO Recommendations, Guidelines and other documents related to the manufacture and quality control of biological substances used in medicine

Annex 1. WHO Recommendations, Guidelines and other documents related to the manufacture and quality control of biological substances used in medicine WHO related to the manufacture and quality control of biological substances used in medicine WHO are intended to provide guidance to those responsible for the production of biological substances as well

More information

Vaccines, Not Just for Babies

Vaccines, Not Just for Babies Vaccines, Not Just for Babies Meg Fisher, MD Medical Director Disclosures I have no relevant financial relationships with the manufacturers of any commercial products or commercial services discussed in

More information

VACCINATION. DR.FATIMA ALKHALEDY M.B.Ch.B;F.I.C.M.S/C.M.

VACCINATION. DR.FATIMA ALKHALEDY M.B.Ch.B;F.I.C.M.S/C.M. VACCINATION DR.FATIMA ALKHALEDY M.B.Ch.B;F.I.C.M.S/C.M. IMMUNIZATION Immunization is defined as the procedure by which the body is prepared to fight against a specific disease. It is used to induce the

More information

Immunizations to Reduce Disease H. Keipp Talbot, M.D., M.P.H.

Immunizations to Reduce Disease H. Keipp Talbot, M.D., M.P.H. Immunizations to Reduce Disease H. Keipp Talbot, M.D., M.P.H. Vanderbilt University School of Medicine 1 DISCLOSURES Financial Relationships with Relevant Commercial Interests Receive research funding

More information

Appendix An Assessment Tool to Determine the Validity of Vaccine Doses

Appendix An Assessment Tool to Determine the Validity of Vaccine Doses Appendix 4.4 - An Assessment Tool to Determine the Validity of Vaccine Doses Note: Refer to the Canadian Immunization Guide and New Brunswick (NB) immunization program directives for recommendations for

More information

Adolescent vaccination strategies

Adolescent vaccination strategies Adolescent vaccination strategies Gregory Hussey Vaccines for Africa Initiative Institute of Infectious Diseases & Molecular Medicine University of Cape Town www.vacfa.uct.ac.za gregory.hussey@uct.ac.za

More information

Public Statement: Medical Policy. Effective Date: 01/01/2012 Revision Date: 03/24/2014 Code(s): Many. Document: ARB0454:04.

Public Statement: Medical Policy. Effective Date: 01/01/2012 Revision Date: 03/24/2014 Code(s): Many. Document: ARB0454:04. ARBenefits Approval: 01/01/2012 Effective Date: 01/01/2012 Revision Date: 03/24/2014 Code(s): Many Medical Policy Title: Immunization Coverage Document: ARB0454:04 Administered by: Public Statement: 1.

More information

Vaccines and other immunological antimicrobial therapy 1

Vaccines and other immunological antimicrobial therapy 1 Vaccines and other immunological antimicrobial therapy 1 Vaccines Vaccine: a biological preparation that provides active acquired immunity to a particular disease. Vaccine typically contains an agent that

More information

Gene Vaccine Dr. Sina Soleimani

Gene Vaccine Dr. Sina Soleimani Gene Vaccine Dr. Sina Soleimani Human Viral Vaccines Quality Control Laboratory (HVVQC) Titles 1. A short Introduction of Vaccine History 2. First Lineage of Vaccines 3. Second Lineage of Vaccines 3. New

More information

UPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES

UPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES DISCLOSURES UPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES Nothing to disclose Kylie Mueller, Pharm.D., BCPS Clinical Specialist, Infectious Diseases Spartanburg Regional Medical Center LEARNING OBJECTIVES

More information

Pregnancy and Shots! Shots! Shots! An Update. Kelli D Barbour, MD 4 December 2015

Pregnancy and Shots! Shots! Shots! An Update. Kelli D Barbour, MD 4 December 2015 Pregnancy and Shots! Shots! Shots! An Update Kelli D Barbour, MD 4 December 2015 Objectives Review recommended adult vaccinations and pregnancy Review recommended immunizations in pregnancy and the puerperium

More information

Update on Vaccine Recommendations. Objectives. Childhood Immunization Schedule At the Turn of the Century. New Horizons in Pediatrics April 30, 2017

Update on Vaccine Recommendations. Objectives. Childhood Immunization Schedule At the Turn of the Century. New Horizons in Pediatrics April 30, 2017 Centers for for Disease Disease Control Control and and Prevention Prevention National Center for Immunization and Respiratory Diseases Update on Vaccine Recommendations New Horizons in Pediatrics April

More information

Medical Coverage Guidelines are subject to change as new information becomes available.

Medical Coverage Guidelines are subject to change as new information becomes available. IMMUNIZATIONS Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline must

More information

Biomedical Engineering for Global Health. Lecture 9 Vaccine development: from idea to product

Biomedical Engineering for Global Health. Lecture 9 Vaccine development: from idea to product Biomedical Engineering for Global Health Lecture 9 Vaccine development: from idea to product Review of lecture 8 Pathogens: Bacteria and Virus Levels of Immunity: Barriers First line of defense Innate

More information

ACIP Meeting Update, New Recommendations and Pending Influenza Season

ACIP Meeting Update, New Recommendations and Pending Influenza Season ACIP Meeting Update, New Recommendations and Pending Influenza Season February 17 th 2011 www.immunizetexas.com ACIP Upcoming Agenda and New Recommendations ACIP (February 23-24 th 2011) Topics for meeting

More information

How and Why Vaccines Are Developed by Industry. Stanley A. Plotkin

How and Why Vaccines Are Developed by Industry. Stanley A. Plotkin How and Why Vaccines Are Developed by Industry Stanley A. Plotkin Merieux 2012 1 Why Vaccines are Different than Drugs 1) Given to healthy people, high safety required 2) Larger governmental role 3) Low

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Routine Immunizations Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 3 References... 7 Effective Date... 4/15/2018

More information

Disclosure Statement. I have no affiliation (financial or otherwise) with a pharmaceutical, medical device or communications organization.

Disclosure Statement. I have no affiliation (financial or otherwise) with a pharmaceutical, medical device or communications organization. Disclosure Statement I have no affiliation (financial or otherwise) with a pharmaceutical, medical device or communications organization. 1 What s new with NACI? Dr. Caroline Quach, NACI Chair Dr. Matthew

More information

Deaths/yr Efficacy Use Prev Deaths/yr. Influenza 36,000 70% 60% 18,000. Pneumonia 40,000 60% 40% 20,000 HBV 6,000 90% 30% 4,000

Deaths/yr Efficacy Use Prev Deaths/yr. Influenza 36,000 70% 60% 18,000. Pneumonia 40,000 60% 40% 20,000 HBV 6,000 90% 30% 4,000 Tetanus, Diptheria, Pertussis,! Measles, Mumps, Rubella, Varicella, HPV, Polio Meningococcus, Pneumococcus,! Influenza, Hepatitis B, Hepatitis A,! H influenza, Rabies, Typhoid,! Yellow Fever, Japanese

More information

Update on Immunizations H. Keipp Talbot, M.D., M.P.H.

Update on Immunizations H. Keipp Talbot, M.D., M.P.H. Update on Immunizations H. Keipp Talbot, M.D., M.P.H. Vanderbilt University Medical Center 1 DISCLOSURES Financial Relationships with Relevant Commercial Interests Receive research funding from Sanofi

More information

Maternal Immunization: Unique considerations of public health value of vaccines given to pregnant women

Maternal Immunization: Unique considerations of public health value of vaccines given to pregnant women Maternal Immunization: Unique considerations of public health value of vaccines given to pregnant women Estimating the full public health value of vaccines Kathleen M. Neuzil, MD, MPH Professor of Medicine

More information

Prevention of Infections in Mothers & Infants

Prevention of Infections in Mothers & Infants Helen Y. Chu, MD MPH Division of Allergy & Infectious Diseases University of Washington Prevention of Infections in Mothers & Infants June 2, 2015 Midwives Association of Washington State Conference Financial

More information

Coverage of Vaccines Medicaid and Child Health Plus Members

Coverage of Vaccines Medicaid and Child Health Plus Members Coverage of Vaccines Medicaid and Child Health Plus Members For children between the ages 0-18, routine recommended vaccinations are covered through Vaccines for Children program [VFC]. Fidelis Care will

More information

Responding to Vaccine Safety Events

Responding to Vaccine Safety Events Responding to Vaccine Safety Events Karen Midthun, MD, Deputy Director Center for Biologics Evaluation and Research, FDA ICDRA Conference Berne, Switzerland September 19, 2008 1 Vision for CBER INNOVATIVE

More information

Immunizations June 5, Brenda Ormesher, MD Infectious Disease Peacehealth Medical Group Springfield, OR

Immunizations June 5, Brenda Ormesher, MD Infectious Disease Peacehealth Medical Group Springfield, OR Immunizations June 5, 2015 Brenda Ormesher, MD Infectious Disease Peacehealth Medical Group Springfield, OR Disclosures None Goals Understand basic public health impact of immunization Recognize types

More information

Young Adults (Ages 18 26)

Young Adults (Ages 18 26) Young Adults (Ages 18 26) Vaccines help prevent many diseases. Some new vaccines are available today that were not in use just a few years ago. By protecting yourself, you help protect everyone around

More information

Healthy People 2020 objectives were released in 2010, with a 10-year horizon to achieve the goals by 2020.

Healthy People 2020 objectives were released in 2010, with a 10-year horizon to achieve the goals by 2020. Appendix 1: Healthy People 2020 Immunization-related Objectives Healthy People provides science-based, 10-year national objectives for improving the health of all Americans. For three decades, Healthy

More information

Needle Facts: Immunization Update Mirada Wilhelm, PharmD Clinical Associate Professor SIUE School of Pharmacy

Needle Facts: Immunization Update Mirada Wilhelm, PharmD Clinical Associate Professor SIUE School of Pharmacy Needle Facts: Immunization Update 2015 Mirada Wilhelm, PharmD Clinical Associate Professor SIUE School of Pharmacy Objectives Pharmacists At the conclusion of this program, the pharmacist will be able

More information

! Need to be extremely safe Even greater issue as disease prevalence wanes or uncommon diseases targeted

! Need to be extremely safe Even greater issue as disease prevalence wanes or uncommon diseases targeted Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital! Need to be extremely safe Even greater issue as disease prevalence wanes or uncommon diseases targeted! Traditionally

More information

1 Principles of Vaccination Immunology and Vaccine-Preventable Diseases... 1 Classification of Vaccines... 4 Selected References...

1 Principles of Vaccination Immunology and Vaccine-Preventable Diseases... 1 Classification of Vaccines... 4 Selected References... 1 Principles of Vaccination Immunology and Vaccine-Preventable Diseases... 1 Classification of Vaccines... 4 Selected References... 7 2 General Recommendations on Immunization Timing and Spacing of Vaccines...

More information

How does the body defend itself?

How does the body defend itself? Prevention of Infection 2 Immunisation 3 rd BDS B. Martin Major World Causes Of Death COUNTRIES Developing Developed Total x10-6 Population 5400 (80%) 1200 (20%) 6600 CAUSE OF DEATH % % % Infectious diseases

More information

Transforming The Approach to Vaccines and Protein- Based Therapeutics. Alain Doucet, Ph.D. Manager, Process Development, Medicago

Transforming The Approach to Vaccines and Protein- Based Therapeutics. Alain Doucet, Ph.D. Manager, Process Development, Medicago Transforming The Approach to Vaccines and Protein- Based Therapeutics Alain Doucet, Ph.D. Manager, Process Development, Medicago 2018-08-15 1 Medicago Overview 2 Novel Technologies 3 Robust Pipeline 2

More information

RECOMMENDED IMMUNIZATIONS

RECOMMENDED IMMUNIZATIONS Recommended Immunization Schedule for Persons Aged 0 Through 6 Years United States 2010 1 2 4 6 12 15 18 19 23 2 3 4 6 Vaccine Age Birth month months months months months months months months years years

More information

HELPING DELIVER LIFE-CHANGING THERAPIES VACCINE DEVELOPMENT

HELPING DELIVER LIFE-CHANGING THERAPIES VACCINE DEVELOPMENT HELPING DELIVER LIFE-CHANGING THERAPIES VACCINE DEVELOPMENT PROVIDING COMPREHENSIVE SOLUTIONS IN A COMPLEX ENVIRONMENT With more than 25 years of vaccine development experience for both government and

More information

Immunization Update 2017 Adult Clinical Learning Day. Tamara Sheffield, MD, MPA, MPH

Immunization Update 2017 Adult Clinical Learning Day. Tamara Sheffield, MD, MPA, MPH Immunization Update 2017 Adult Clinical Learning Day Tamara Sheffield, MD, MPA, MPH Highlighted Topics Influenza Vaccine Errors 2 Dose HPV Community protection Tdap in pregnancy Meningococcal Future Recs

More information

Viral vaccines. Lec. 3 أ.د.فائزة عبد هللا مخلص

Viral vaccines. Lec. 3 أ.د.فائزة عبد هللا مخلص Lec. 3 أ.د.فائزة عبد هللا مخلص Viral vaccines 0bjectives 1-Define active immunity. 2-Describe the methods used for the preparation of attenuated live & killed virus vaccines. 3- Comparison of Characteristics

More information

Kenneth McCall, BSPharm, PharmD Associate Professor UNE President Maine Pharmacy Association

Kenneth McCall, BSPharm, PharmD Associate Professor UNE President Maine Pharmacy Association Kenneth McCall, BSPharm, PharmD Associate Professor UNE President Maine Pharmacy Association Objectives Discuss the gap between current rates and Healthy People 2020 goals for vaccinations. Categorize

More information

Assessment of Influenza Vaccine Production Compatibilities

Assessment of Influenza Vaccine Production Compatibilities United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Assessment of Influenza Vaccine Production Compatibilities Joshua Speidel, PhD Influenza

More information

Please read Chapters 5, 6 and 7 of your vaccine text for next Wednesday s lecture. Chapters 9, 17 and 8 for next Friday s lectures

Please read Chapters 5, 6 and 7 of your vaccine text for next Wednesday s lecture. Chapters 9, 17 and 8 for next Friday s lectures Valerie Daggett Please read Chapters 5, 6 and 7 of your vaccine text for next Wednesday s lecture Chapters 9, 17 and 8 for next Friday s lectures ppt files for first 2 lectures Past exams Principles of

More information

24 26 January 2013, Hong Kong SAR, CHINA. TITLE from VIEW and SLIDE MASTER February 27, 2013

24 26 January 2013, Hong Kong SAR, CHINA. TITLE from VIEW and SLIDE MASTER February 27, 2013 The first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses 24 26 January 2013, Hong Kong SAR, CHINA 1 TITLE

More information

Lichenase: a versatile, stable carrier molecule for vaccine and reagent development

Lichenase: a versatile, stable carrier molecule for vaccine and reagent development Lichenase: a versatile, stable carrier molecule for vaccine and reagent development R. Mark Jones Center for Molecular Biotechnology, Fraunhofer USA New Cells, New Vaccines VII, From Protein to Product

More information

What s New With Immunizations

What s New With Immunizations What s New With Immunizations 2018 Annual Update COURTNEY A. ROBERTSON, PHARMD, BCPS CLINICAL ASSISTANT PROFESSOR UNIVERSITY OF LOUISIANA AT MONROE COLLEGE OF PHARMACY Disclosures No financial disclosures

More information

VACCINES-WHAT HAS HAPPENED IN THE LAST YEAR. Mark H. Sawyer UCSD School of Medicine Rady Children s Hospital San Diego

VACCINES-WHAT HAS HAPPENED IN THE LAST YEAR. Mark H. Sawyer UCSD School of Medicine Rady Children s Hospital San Diego VACCINES-WHAT HAS HAPPENED IN THE LAST YEAR Mark H. Sawyer UCSD School of Medicine Rady Children s Hospital San Diego LOTS HAS HAPPENED AND IT CAN BE A LITTLE CONFUSING Some people can get 2 doses of HPV

More information

CURRENT DEVELOPMENT IN PEDIATRIC VACCINATION

CURRENT DEVELOPMENT IN PEDIATRIC VACCINATION Univ.-Prof. Dr. med. Heinz-J. SCHMITT Senior Medical Director, Pfizer Vaccines Europe Thessaloniki, February 20th, 2018 CURRENT DEVELOPMENT IN PEDIATRIC VACCINATION Selected Case Fatality Rates Germany,

More information

Immunizations for Children and Teens with Suppressed Immune Systems

Immunizations for Children and Teens with Suppressed Immune Systems Immunizations for Children and Teens with Suppressed Immune Systems Your child is starting treatment that will suppress the immune system. This will affect how your child s body responds to routine immunizations

More information

21 st Century Vaccine Challenges

21 st Century Vaccine Challenges 21 st Century Vaccine Challenges Presentation by Rosalyn Singleton MD, ANTHC Slides adapted from original powerpoint by: Carrie L. Byington, MD HA and Edna Benning Presidential Professor of Pediatrics

More information

Vaccine. Design and Manufacturing. Liting Bi. https://en.wikipedia.org/wiki/vaccine

Vaccine. Design and Manufacturing. Liting Bi. https://en.wikipedia.org/wiki/vaccine Vaccine Design and Manufacturing Liting Bi https://en.wikipedia.org/wiki/vaccine 1 Outline Vaccine Intro. 4 Vaccine Types 2 Manufacturing Methods 2 Tests & Applications Take-home messages 2 https://www.youtube.com/watch?v=t_me5ef0ne4

More information

National Immunization Update

National Immunization Update National Immunization Update H. Cody Meissner, M.D. Professor of Pediatrics Tufts Medical Center Boston, MA October 18, 2018 23 rd MIAP Immunization Conference Framingham, MA Disclaimers/Disclosure I have

More information

National Immunization Update

National Immunization Update National Immunization Update H. Cody Meissner, M.D. Professor of Pediatrics Tufts Medical Center Boston, MA October 18, 2018 23 rd MIAP Immunization Conference Framingham, MA Disclaimers/Disclosure I have

More information

CPT 2016 Code Changes

CPT 2016 Code Changes CPT 2016 Code Changes Code Changes - Medicine New CPT 2016 New Codes Code Description 69209 Removal impacted cerumen using irrigation/lavage, unilateral 90620 Meningococcal recombinant protein and outer

More information

M I C R O B I O L O G Y

M I C R O B I O L O G Y ninth edition TORTORA FUNKE CASE M I C R O B I O L O G Y a n i n t r o d u c t i o n 18 Practical Applications of Immunology PowerPoint Lecture Slide Presentation prepared by Christine L. Case Vaccine

More information

Benefit Interpretation

Benefit Interpretation Benefit Interpretation Subject: Part B vs. Part D Vaccines Issue Number: BI-039 Applies to: Medicare Advantage Effective Date: May 1, 2017 Attachments: Part B Vaccines Diagnosis Code Limits Table of Contents

More information

VACCINE FACT BOOK 2012

VACCINE FACT BOOK 2012 VACCINE FACT BOOK 2012 Preface Prevention is better than cure is a proverb in many other languages as well. This idea is central to the development of vaccines, which have transformed human health since

More information

Immunization Update: New CDC Recommendations. Blaise L. Congeni M.D. 2012

Immunization Update: New CDC Recommendations. Blaise L. Congeni M.D. 2012 Immunization Update: New CDC Recommendations Blaise L. Congeni M.D. 2012 Polysaccharide Vaccines Vaccine Hib capsule polysaccharide PRP (polyribose ribitol phosphate) Not protective in infants

More information

Immunization Update 2016 Clinical Learning Day. Tamara Sheffield, MD, MPA, MPH

Immunization Update 2016 Clinical Learning Day. Tamara Sheffield, MD, MPA, MPH Immunization Update 2016 Clinical Learning Day Tamara Sheffield, MD, MPA, MPH Disclosure I do not have any relevant financial relationships with any commercial interests I am a Medical Director employed

More information

2016/17 Vaccination and Immunisation list of additional services and enhanced services

2016/17 Vaccination and Immunisation list of additional services and enhanced services 2016/17 Vaccination and Immunisation list of additional services and enhanced services 2016/17 Vaccination and Immunisation list of additional services and enhanced services Version number: 1 First published:

More information

PREVENTIVE IMMUNIZATIONS. PREVENTIVE IMMUNIZATIONS These codes do not have a diagnosis code requirement for preventive benefits to apply.

PREVENTIVE IMMUNIZATIONS. PREVENTIVE IMMUNIZATIONS These codes do not have a diagnosis code requirement for preventive benefits to apply. An immunization that does not fall under one of the exclusions in the Certificate of Coverage is considered covered after the following conditions are satisfied: (1) FDA approval; (2) explicit ACIP recommendation

More information

November 13, 2009 Licensure, Evaluation, and Adverse Event Monitoring of the 2009 H1N1 Influenza Vaccine By Matthew Watson and Jennifer Nuzzo

November 13, 2009 Licensure, Evaluation, and Adverse Event Monitoring of the 2009 H1N1 Influenza Vaccine By Matthew Watson and Jennifer Nuzzo www.upmc-biosecurity.org www.upmc-cbn.org November 13, 2009 Licensure, Evaluation, and Adverse Event Monitoring of the 2009 H1N1 Influenza Vaccine By Matthew Watson and Jennifer Nuzzo In response to the

More information

Influenza Update. Lisa Grohskopf, MD, MPH Influenza Division, CDC. NAICP Call 6 October 2015

Influenza Update. Lisa Grohskopf, MD, MPH Influenza Division, CDC. NAICP Call 6 October 2015 Influenza Update Lisa Grohskopf, MD, MPH Influenza Division, CDC NAICP Call 6 October 2015 National Center for Immunization and Respiratory Diseases Influenza Division Overview Surveillance update ACIP

More information

Contents. Part One Vaccine Use. Acknowledgments

Contents. Part One Vaccine Use. Acknowledgments Contents Foreword Acknowledgments xiii xv Part One Vaccine Use Chapter 1 Introduction 1 To Vaccinate or Not to Vaccinate? 2 Not the Last Word 3 Permission Granted 4 Your Right to Know 4 The Goals of This

More information

A Universal Manufacturing Platform For Vaccine Production

A Universal Manufacturing Platform For Vaccine Production A Universal Manufacturing Platform For Vaccine Production Manon M.J. Cox 18Mar2013 Topics The Company Baculovirus Technology Platform (BEVS) Flublok and Pandemic Influenza Other vaccines opportunities

More information

Immunization Update 2017 Peds Clinical Learning Day. Tamara Sheffield, MD, MPA, MPH

Immunization Update 2017 Peds Clinical Learning Day. Tamara Sheffield, MD, MPA, MPH Immunization Update 2017 Peds Clinical Learning Day Tamara Sheffield, MD, MPA, MPH Highlighted Topics Influenza Vaccine Errors 2 Dose HPV Community protection Tdap in pregnancy Hepatitis B Meningococcal

More information

What DO the childhood immunization footnotes reveal? Questions and answers

What DO the childhood immunization footnotes reveal? Questions and answers What DO the childhood immunization footnotes reveal? Questions and answers Stanley E. Grogg, DO, FACOP, FAAP he Advisory Committee on Immunization Practices (ACIP) recommends the childhood vaccination

More information

2017/18 Immunisation programmes list of additional and enhanced services

2017/18 Immunisation programmes list of additional and enhanced services 2017/18 Immunisation programmes list of additional and enhanced services 2017/18 Vaccination and Immunisation list of additional and enhanced services Version number: 1 First published: April 2017 Prepared

More information

PREVENTIVE IMMUNIZATIONS. PREVENTIVE IMMUNIZATIONS These codes do not have a diagnosis code requirement for preventive benefits to apply.

PREVENTIVE IMMUNIZATIONS. PREVENTIVE IMMUNIZATIONS These codes do not have a diagnosis code requirement for preventive benefits to apply. An immunization that does not fall under one of the exclusions in the Certificate of Coverage is considered covered after the following conditions are satisfied: (1) FDA approval; (2) explicit ACIP recommendation

More information

After participating in the conference, you should have improved your knowledge of, and enhanced your competence to:

After participating in the conference, you should have improved your knowledge of, and enhanced your competence to: Vaccine Preventable Diseases Shouldn t Happen in Pregnancy: Immunizations for Mother and Baby Laura E. Riley, M.D. Associate Professor of Obstetrics and Gynecology Harvard Medical School Division of Maternal

More information

Vaccines: Health care workers, influenza, new developments. David W Smith PathWest Laboratory Medicine WA University of Western Australia

Vaccines: Health care workers, influenza, new developments. David W Smith PathWest Laboratory Medicine WA University of Western Australia Vaccines: Health care workers, influenza, new developments David W Smith PathWest Laboratory Medicine WA University of Western Australia Why vaccinate health care workers? Protects their patients by reducing

More information

GENERAL IMMUNIZATION GUIDE FOR CHILDCARE PROVIDERS August 2018 **CHILD VACCINES** DIPHTHERIA, TETANUS, PERTUSSIS VACCINES

GENERAL IMMUNIZATION GUIDE FOR CHILDCARE PROVIDERS August 2018 **CHILD VACCINES** DIPHTHERIA, TETANUS, PERTUSSIS VACCINES GENERAL IMMUNIZATION GUIDE FOR CHILDCARE PROVIDERS August 2018 **CHILD VACCINES** DIPHTHERIA, TETANUS, PERTUSSIS VACCINES DTaP: Diphtheria, Tetanus, acellular Pertussis Vaccine Infanrix Licensed in 1997

More information

VACCINATION FOR WOMEN (ADOLESCENCE TO SENESCENCE)

VACCINATION FOR WOMEN (ADOLESCENCE TO SENESCENCE) VACCINATION FOR WOMEN (ADOLESCENCE TO SENESCENCE) Dr.T.K.SHAANTHY GUNASINGH M.D., D.G.O., FICOG PROFESSOR AND HEAD OF THE DEPARTMENT OF OBSTETRICS AND GYNAECOLOGY PROGRAMME DIRECTOR CENTRE OF EXCELLENCE

More information

Immunization Update Disclosures. Candice Robinson, MD, MPH Medical Officer Immunization Services Division 5/12/2017

Immunization Update Disclosures. Candice Robinson, MD, MPH Medical Officer Immunization Services Division 5/12/2017 Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Immunization Update 2017 Candice Robinson, MD, MPH Medical Officer Immunization Services Division Western

More information

Objectives 1. Become familiar with current immunization schedules for children

Objectives 1. Become familiar with current immunization schedules for children Sarah Matches, DO, FAAP Assistant Professor UNTHSC, Dept. of Pediatrics Objectives 1. Become familiar with current immunization schedules for children 2. Describe the international progress in reducing

More information

June 2016 ACIP Immunization Update

June 2016 ACIP Immunization Update June 2016 ACIP Immunization Update Stephan L. Foster, PharmD, FAPhA CAPT (Ret) USPHS Professor, University of Tennessee College of Pharmacy Liaison Member, CDC Advisory Committee on Immunization Practices

More information

Advisory Committee on Immunization Practices VACCINE ACRONYMS

Advisory Committee on Immunization Practices VACCINE ACRONYMS May 1, 2015 Vaccine Acronyms Page 1 of 5 Advisy Committee on Immunization Practices VACCINE ACRONYMS Vaccines Included in the Immunization Schedules f Children, Adolescents, and Adults Following is a table

More information

2018/19 Immunisation programmes list of additional and enhanced services

2018/19 Immunisation programmes list of additional and enhanced services 2018/19 Immunisation programmes list of additional and enhanced services 2018/19 Vaccination and Immunisation list of additional and enhanced services Version number: 1 First published: April 2018 Prepared

More information

Nothing to disclose. Vaccinations for Adults and Adolescents: An Update. Key Resource

Nothing to disclose.  Vaccinations for Adults and Adolescents: An Update. Key Resource Vaccinations for Adults and Adolescents: An Update Nothing to disclose. Lisa G. Winston, MD Professor of Medicine, University of California, San Francisco Vice Chief, Inpatient Medical Services and Hospital

More information

A. Children born in 1942 B. Children born in 1982 C. Children born in 2000 D. Children born in 2010

A. Children born in 1942 B. Children born in 1982 C. Children born in 2000 D. Children born in 2010 Who do you think received the most immunologic components in vaccines? Development of which vaccine slowed after the invention of antibiotics? A. Children born in 1942 B. Children born in 1982 C. Children

More information

US Efforts in Vaccine Safety. Roger Baxter, MD California Immunization Coalition Summit 2011

US Efforts in Vaccine Safety. Roger Baxter, MD California Immunization Coalition Summit 2011 US Efforts in Vaccine Safety Roger Baxter, MD California Immunization Coalition Summit 2011 Conflicts of interest I receive research grants from Sanofi Pasteur, GSK, Merck, MedImmune, Novartis, Pfizer,

More information

Immunization Update Dennis D. Stanley, BPharm Publix Pharmacy Vaccine and Travel Health Specialist

Immunization Update Dennis D. Stanley, BPharm Publix Pharmacy Vaccine and Travel Health Specialist Immunization Update 2018 Dennis D. Stanley, BPharm Publix Pharmacy Vaccine and Travel Health Specialist Disclosures Merck speakers bureau Vaxserve speakers bureau Mrs. Jones shows up for her second ShingRix

More information

ACIP Meeting June 22, 2016 Influenza Session: Key Points

ACIP Meeting June 22, 2016 Influenza Session: Key Points Update: CDC s Advisory Committee on Immunization Practices (ACIP) voted in favor of an interim recommendation that live attenuated influenza vaccine (LAIV), also known as the nasal spray flu vaccine, should

More information

Armed Services Blood Program Immunization List

Armed Services Blood Program Immunization List Immunization List NOTICE: The Department of Defense (DoD) assumes no risk for the use of this information by non-dod personnel, blood programs, or individual medical institutions. The use of this information

More information

Vaccine Innovation: Challenges and Opportunities to Protect Health. Julie Louise Gerberding, M.D., M.P.H President, Merck Vaccines

Vaccine Innovation: Challenges and Opportunities to Protect Health. Julie Louise Gerberding, M.D., M.P.H President, Merck Vaccines Vaccine Innovation: Challenges and Opportunities to Protect Health Julie Louise Gerberding, M.D., M.P.H President, Merck Vaccines Protecting Health with Vaccines HEALTH IMPROVEMENT Population Impact Guidelines

More information